Orchestra BioMed Holdings, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David Hochman
- Full Time Employees
- 86
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 150 Union Square Drive New Hope PA United States of America 18938
- IPO Date
- Aug 4, 2020
- CIK
- 0001814114
- Website
- orchestrabiomed.com
- Similar Companies
- Business
- Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing transformative therapeutic products addressing large unmet clinical needs in procedure-based medicine. The company’s core products include BackBeat Cardiac Neuromodulation Therapy (CNT™) also known as Atrioventricular Interval Modulation (AVIM) therapy, a late-stage bioelectronic therapy designed to substantially and persistently lower blood pressure for the treatment of hypertension in pacemaker patients, and the Virtue Sirolimus AngioInfusion Balloon (SAB), a proprietary drug/device combination product candidate delivering an extended-release formulation of sirolimus for the treatment of atherosclerotic artery disease without requiring balloon coating or a permanent implant. Additionally, Orchestra BioMed pursues development of bioelectronic therapies for heart failure and offers minimally invasive surgical enabling devices as well as medical devices for gastrointestinal tract cleansing during endoscopy procedures. The company forms strategic collaborations for development and commercialization with leading global medical device companies, including partnership agreements with Medtronic for AVIM therapy and Terumo Corporation for Virtue SAB. Recent major developments include securing $147.6 million in proceeds and committed capital through strategic transactions and a new financial partnership with Ligand Pharmaceuticals and expanding the collaboration with Medtronic, enabling the advancement of its late-stage cardiology programs. Orchestra BioMed also entered into a mediation process with Terumo to resolve partnership restructuring and continues active enrollment in pivotal clinical trials for its flagship products, targeting global commercialization goals. Founded in 2017 and headquartered in New Hope, Pennsylvania, Orchestra BioMed operates primarily in the United States within the biotechnology and healthcare sector.
Company News
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
OBIO's Capital Access Advisory Program (CAAP®) Reaches Milestone with $1 Billion Raised by High-Growth Life Sciences and Health Tech Ventures
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates
Affinity Asset Advisors LLC Lowers Holdings in Orchestra BioMed Holdings, Inc. $OBIO
Orchestra BioMed: Nearing The First Of Two Pivotal Readouts
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy